Photodynamic therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration

Mong Ping Shyong, Fenq Lih Lee, Shih Jen Chen, Tao Hsin Tung, Der Chong Tsai, Wen-Ming Hsu

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Background: To evaluate the safety and efficacy of verteporfin photodynamic therapy (PDT) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods: We retrospectively reviewed the chart records and fluorescein angiography of patients with subfoveal CNV who were treated with verteporfin PDT between September 2001 and March 2003 and who completed at least 1 year of follow-up. The primary efficacy outcomes were the proportions of patients whose Snellen visual acuities had more than 1 line increase, no change or more than 1 line decrease 1 year after study entry compared with their baseline examinations. The secondary efficacy outcome was the changes in the logarithm of the minimum angle of resolution visual acuities at 1-year follow-up. Complications were monitored and tabulated. Results: Forty-eight eyes of 48 patients with subfoveal CNV secondary to AMD were enrolled in this study. The mean follow-up was 12.56 ± 1.37 months. At their last visit, 10.4% of eyes had more than 1 line improvement in Snellen visual acuity, 72.9% of eyes had no change, and 16.7% experienced more than 1 line of visual acuity loss (7 eyes lost < 3 lines of Snellen visual acuity, 1 eye lost between 3 and 6 lines). None experienced more than 6 lines of visual loss. There was no statistically significant difference between baseline and final visual acuity for eyes with predominantly classic CNV, minimally classic CNV and occult without classic CNV (Wilcoxon Signed Rank test, p = 0.59). There was a positive correlation between baseline visual acuity and final visual outcome (Kruskal-Wallis test, p = 0.002). No severe systemic and ocular adverse events were encountered. Conclusion: Of our patients with subfoveal CNV secondary to AMD, 83.3% could maintain or improve their visual acuity 1 year after verteporfin PDT. The risk of deterioration in visual acuity due to subfoveal CNV could be reduced by verteporfin PDT. Baseline visual acuity is significantly correlated with the final proportion of visual outcome.

Original languageEnglish
Pages (from-to)419-424
Number of pages6
JournalJournal of the Chinese Medical Association
Volume68
Issue number9
DOIs
Publication statusPublished - Jan 1 2005
Externally publishedYes

Fingerprint

Choroidal Neovascularization
Photochemotherapy
Macular Degeneration
Visual Acuity
Fluorescein Angiography
Nonparametric Statistics
Safety

Keywords

  • Age-related macular degeneration
  • Choroidal neovascularization
  • Photodynamic therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Photodynamic therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. / Shyong, Mong Ping; Lee, Fenq Lih; Chen, Shih Jen; Tung, Tao Hsin; Tsai, Der Chong; Hsu, Wen-Ming.

In: Journal of the Chinese Medical Association, Vol. 68, No. 9, 01.01.2005, p. 419-424.

Research output: Contribution to journalReview article

Shyong, Mong Ping ; Lee, Fenq Lih ; Chen, Shih Jen ; Tung, Tao Hsin ; Tsai, Der Chong ; Hsu, Wen-Ming. / Photodynamic therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. In: Journal of the Chinese Medical Association. 2005 ; Vol. 68, No. 9. pp. 419-424.
@article{b10ff27b25034f23998e6b5eda0fc778,
title = "Photodynamic therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration",
abstract = "Background: To evaluate the safety and efficacy of verteporfin photodynamic therapy (PDT) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods: We retrospectively reviewed the chart records and fluorescein angiography of patients with subfoveal CNV who were treated with verteporfin PDT between September 2001 and March 2003 and who completed at least 1 year of follow-up. The primary efficacy outcomes were the proportions of patients whose Snellen visual acuities had more than 1 line increase, no change or more than 1 line decrease 1 year after study entry compared with their baseline examinations. The secondary efficacy outcome was the changes in the logarithm of the minimum angle of resolution visual acuities at 1-year follow-up. Complications were monitored and tabulated. Results: Forty-eight eyes of 48 patients with subfoveal CNV secondary to AMD were enrolled in this study. The mean follow-up was 12.56 ± 1.37 months. At their last visit, 10.4{\%} of eyes had more than 1 line improvement in Snellen visual acuity, 72.9{\%} of eyes had no change, and 16.7{\%} experienced more than 1 line of visual acuity loss (7 eyes lost < 3 lines of Snellen visual acuity, 1 eye lost between 3 and 6 lines). None experienced more than 6 lines of visual loss. There was no statistically significant difference between baseline and final visual acuity for eyes with predominantly classic CNV, minimally classic CNV and occult without classic CNV (Wilcoxon Signed Rank test, p = 0.59). There was a positive correlation between baseline visual acuity and final visual outcome (Kruskal-Wallis test, p = 0.002). No severe systemic and ocular adverse events were encountered. Conclusion: Of our patients with subfoveal CNV secondary to AMD, 83.3{\%} could maintain or improve their visual acuity 1 year after verteporfin PDT. The risk of deterioration in visual acuity due to subfoveal CNV could be reduced by verteporfin PDT. Baseline visual acuity is significantly correlated with the final proportion of visual outcome.",
keywords = "Age-related macular degeneration, Choroidal neovascularization, Photodynamic therapy",
author = "Shyong, {Mong Ping} and Lee, {Fenq Lih} and Chen, {Shih Jen} and Tung, {Tao Hsin} and Tsai, {Der Chong} and Wen-Ming Hsu",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/S1726-4901(09)70157-1",
language = "English",
volume = "68",
pages = "419--424",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "9",

}

TY - JOUR

T1 - Photodynamic therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration

AU - Shyong, Mong Ping

AU - Lee, Fenq Lih

AU - Chen, Shih Jen

AU - Tung, Tao Hsin

AU - Tsai, Der Chong

AU - Hsu, Wen-Ming

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background: To evaluate the safety and efficacy of verteporfin photodynamic therapy (PDT) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods: We retrospectively reviewed the chart records and fluorescein angiography of patients with subfoveal CNV who were treated with verteporfin PDT between September 2001 and March 2003 and who completed at least 1 year of follow-up. The primary efficacy outcomes were the proportions of patients whose Snellen visual acuities had more than 1 line increase, no change or more than 1 line decrease 1 year after study entry compared with their baseline examinations. The secondary efficacy outcome was the changes in the logarithm of the minimum angle of resolution visual acuities at 1-year follow-up. Complications were monitored and tabulated. Results: Forty-eight eyes of 48 patients with subfoveal CNV secondary to AMD were enrolled in this study. The mean follow-up was 12.56 ± 1.37 months. At their last visit, 10.4% of eyes had more than 1 line improvement in Snellen visual acuity, 72.9% of eyes had no change, and 16.7% experienced more than 1 line of visual acuity loss (7 eyes lost < 3 lines of Snellen visual acuity, 1 eye lost between 3 and 6 lines). None experienced more than 6 lines of visual loss. There was no statistically significant difference between baseline and final visual acuity for eyes with predominantly classic CNV, minimally classic CNV and occult without classic CNV (Wilcoxon Signed Rank test, p = 0.59). There was a positive correlation between baseline visual acuity and final visual outcome (Kruskal-Wallis test, p = 0.002). No severe systemic and ocular adverse events were encountered. Conclusion: Of our patients with subfoveal CNV secondary to AMD, 83.3% could maintain or improve their visual acuity 1 year after verteporfin PDT. The risk of deterioration in visual acuity due to subfoveal CNV could be reduced by verteporfin PDT. Baseline visual acuity is significantly correlated with the final proportion of visual outcome.

AB - Background: To evaluate the safety and efficacy of verteporfin photodynamic therapy (PDT) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods: We retrospectively reviewed the chart records and fluorescein angiography of patients with subfoveal CNV who were treated with verteporfin PDT between September 2001 and March 2003 and who completed at least 1 year of follow-up. The primary efficacy outcomes were the proportions of patients whose Snellen visual acuities had more than 1 line increase, no change or more than 1 line decrease 1 year after study entry compared with their baseline examinations. The secondary efficacy outcome was the changes in the logarithm of the minimum angle of resolution visual acuities at 1-year follow-up. Complications were monitored and tabulated. Results: Forty-eight eyes of 48 patients with subfoveal CNV secondary to AMD were enrolled in this study. The mean follow-up was 12.56 ± 1.37 months. At their last visit, 10.4% of eyes had more than 1 line improvement in Snellen visual acuity, 72.9% of eyes had no change, and 16.7% experienced more than 1 line of visual acuity loss (7 eyes lost < 3 lines of Snellen visual acuity, 1 eye lost between 3 and 6 lines). None experienced more than 6 lines of visual loss. There was no statistically significant difference between baseline and final visual acuity for eyes with predominantly classic CNV, minimally classic CNV and occult without classic CNV (Wilcoxon Signed Rank test, p = 0.59). There was a positive correlation between baseline visual acuity and final visual outcome (Kruskal-Wallis test, p = 0.002). No severe systemic and ocular adverse events were encountered. Conclusion: Of our patients with subfoveal CNV secondary to AMD, 83.3% could maintain or improve their visual acuity 1 year after verteporfin PDT. The risk of deterioration in visual acuity due to subfoveal CNV could be reduced by verteporfin PDT. Baseline visual acuity is significantly correlated with the final proportion of visual outcome.

KW - Age-related macular degeneration

KW - Choroidal neovascularization

KW - Photodynamic therapy

UR - http://www.scopus.com/inward/record.url?scp=25444443406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444443406&partnerID=8YFLogxK

U2 - 10.1016/S1726-4901(09)70157-1

DO - 10.1016/S1726-4901(09)70157-1

M3 - Review article

C2 - 16187598

AN - SCOPUS:25444443406

VL - 68

SP - 419

EP - 424

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 9

ER -